CTLA4 and breast carcinoma: It has been reported that SLC-0111 by reducing extracellular acidification, augmented the effects of immune-checkpoint inhibitors anti–PD-1 and anti–CTLA-4 on enhancement of Th1 response and reduction of melanoma tumor growth and breast cancer metastasis [13].